[ O
1 B
, I
25 I
- I
Dihydroxyvitamin I
D3 I
receptors I
in O
lymphocytes O
and O
T O
- O
and O
B O
- O
lymphocyte O
count O
in O
patients O
with O
glomerulonephritis O
] O

Kappa B
B I
- I
specific I
DNA I
binding I
proteins I
: O
role O
in O
the O
regulation O
of O
human B
interleukin I
- I
2 I
gene I
expression O
. O

This O
suggests O
that O
the O
constitutive O
OCTA B
- I
binding I
factor I
NF I
- I
A1 I
can O
activate O
transcription O
of O
the O
Ig B
promoter I
and O
that O
B O
- O
cell O
- O
specific O
transcription O
of O
this O
promoter O
, O
at O
least O
in O
vitro O
, O
is O
partially O
due O
to O
a O
quantitative O
difference O
in O
the O
amount O
of O
OCTA B
- I
binding I
protein I
. O

Identification O
and O
purification O
of O
a O
human B
immunoglobulin I
- I
enhancer I
- I
binding I
protein I
( O
NF B
- I
kappa I
B I
) O
that O
activates O
transcription O
from O
a O
human B
immunodeficiency I
virus I
type I
1 I
promoter I
in O
vitro O
. O

Granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
. O

We O
show O
that O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
1 O
, O
25 O
[ O
OH O
] O
2D3 O
) O
, O
the O
most O
hormonally O
active O
metabolite O
of O
vitamin O
D3 O
, O
modulates O
sensitively O
and O
specifically O
both O
the O
protein O
and O
messenger B
RNA I
accumulation O
of O
the O
multilineage B
growth I
factor I
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
. O

Interaction O
of O
cell B
- I
type I
- I
specific I
nuclear I
proteins I
with O
immunoglobulin B
VH I
promoter I
region I
sequences I
. O

One O
element O
is O
located O
in O
the O
intron O
between O
the O
variable O
( O
V O
) O
and O
constant O
( O
C O
) O
regions O
of O
both O
heavy B
and I
kappa I
light I
- I
chain I
genes I
and O
acts O
as O
a O
transcriptional O
enhancer O
. O

Recognition O
of O
herpes B
simplex I
virus I
type I
2 I
tegument I
proteins I
by O
CD4 O
T O
cells O
infiltrating O
human O
genital O
herpes O
lesions O
. O

Using O
the O
1G5 O
cell O
line O
harbouring O
the O
luciferase O
reporter O
gene O
under O
the O
control O
of O
the O
HIV B
- I
1 I
LTR I
, O
it O
was O
first O
found O
that O
culture O
protein O
filtrates O
( O
CFP O
) O
from O
M O
. O
tuberculosis O
or O
purified O
ManLAM O
could O
activate O
HIV B
- I
1 I
LTR I
- I
dependent I
gene I
expression O
unlike O
similarly O
prepared O
CFP O
extracts O
devoid O
of O
ManLAM O
. O

Transcriptional O
regulation O
by O
C B
/ I
EBP I
alpha I
and I
- I
beta I
in O
the O
expression O
of O
the O
gene O
for O
the O
MRP14 B
myeloid I
calcium I
binding I
protein I
. O

An O
anti B
- I
C I
/ I
EBP I
delta I
antibody I
had O
no O
effect O
on O
the O
complex O
in O
either O
cell O
. O

Thus O
, O
it O
was O
concluded O
that O
C B
/ I
EBP I
alpha I
and I
- I
beta I
were O
able O
to O
bind O
to O
the O
C B
/ I
EBP I
motif I
, O
and O
that O
C B
/ I
EBP I
alpha I
bound O
to O
the O
motif O
in O
THP O
- O
1 O
cells O
and O
C B
/ I
EBP I
beta I
bound O
to O
that O
in O
the O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
. O

There O
was O
minimal O
expression O
of O
HSD3B1 B
and O
HSD3B2 B
( O
3beta B
- I
hydroxysteroid I
dehydrogenase I
I I
and I
II I
) O
in O
B O
- O
LCL O
and O
T O
cells O
. O

Differences O
in O
the O
phenotypes O
of O
a O
null O
and O
a O
dominant B
negative I
( I
DN I
) I
Ikaros I
mutation I
provide O
insight O
into O
a O
regulatory O
network O
through O
which O
Ikaros B
proteins I
exert O
their O
effects O
in O
development O
. O

Chloramphenicol B
acetyltransferase I
assays O
indicated O
that O
NF B
- I
kappaB I
- I
like I
element I
1 I
was O
Tax B
- O
responsive O
, O
although O
the O
activity O
was O
lower O
than O
that O
the O
native B
promoter I
. O

NF B
- I
kappaB I
- O
like O
element O
2 O
elevated O
promoter O
activity O
when O
combined O
with O
NF B
- I
kappaB I
- I
like I
element I
1 I
, O
indicating O
cooperative O
function O
of O
the O
elements O
for O
maximum O
promoter O
function O
. O

The O
paired B
box I
containing I
gene I
PAX B
- I
5 I
encodes O
the O
transcription B
factor I
BSAP B
( O
B B
- I
cell I
- I
specific I
activator I
protein I
) O
, O
which O
plays O
a O
key O
role O
in O
B O
- O
lymphocyte O
development O
. O

Relative O
levels O
of O
nm23 B
- I
H1 I
and I
- I
H2 I
mRNA I
extracted O
from O
the O
patient O
' O
s O
peripheral O
blood O
mononuclear O
cells O
and O
bone O
marrow O
mononuclear O
cells O
were O
measured O
by O
quantitative O
reverse O
transcriptase O
polymerase O
chain O
reaction O
. O

At O
blastic O
crisis O
, O
however O
, O
expression O
of O
both O
nm23 B
- I
H1 I
and I
- I
H2 I
mRNA I
was O
elevated O
to O
about O
three O
to O
nine O
times O
of O
that O
at O
the O
chronic O
phase O
. O

Bcl B
- I
3 I
expression O
and O
nuclear O
translocation O
are O
induced O
by O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
and O
erythropoietin B
in O
proliferating O
human O
erythroid O
precursors O
. O

In O
TF O
- O
1 O
cells O
, O
an O
erythroleukemia O
cell O
line O
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
and O
erythropoietin B
( O
Epo B
) O
greatly O
enhanced O
Bcl B
- I
3 I
expression O
at O
both O
the O
protein O
and O
mRNA O
levels O
in O
association O
with O
stimulation O
of O
proliferation O
. O

Overexpression O
of O
Bcl B
- I
3 I
in O
TF O
- O
1 O
cells O
by O
transient O
transfection O
along O
with O
the O
NF B
- I
kappaB I
factors I
p50 I
or I
p52 I
resulted O
in O
significant O
induction O
of O
an O
human B
immunodeficiency I
virus I
- I
type I
1 I
( I
HIV I
- I
1 I
) I
kappaB I
- I
TATA I
- I
luceriferase I
reporter I
plasmid I
, O
demonstrating O
that O
Bcl B
- I
3 I
has O
a O
positive O
role O
in O
transactivation O
of O
kappaB B
- I
containing I
genes I
in O
erythroid O
cells O
. O

Cotransfection O
assays O
with O
the O
TR3 B
/ I
nur77 I
promoter I
sequence I
or O
the O
NBRE B
binding O
motif O
together O
with O
a O
series O
of O
Tax B
mutants O
have O
shown O
that O
Tax B
- O
induced O
TR3 B
/ I
nur77 I
expression O
is O
mediated O
by O
CREB B
/ I
ATF I
- I
related I
transcription I
factors I
. O

PCNSL O
associated O
frequently O
( O
50 O
. O
0 O
% O
) O
with O
mutations O
of O
BCL B
- I
6 I
5 I
' I
noncoding I
regions I
, O
which O
are O
regarded O
as O
a O
marker O
of O
B O
- O
cell O
transition O
through O
the O
germinal O
center O
( O
GC O
) O
. O

Furthermore O
, O
the O
activity O
of O
transcription B
factors I
regulating O
the O
IL B
- I
2 I
promoter I
- I
enhancer I
region I
including O
activation B
protein I
- I
1 I
, O
CD28 B
response I
element I
and O
nuclear B
factor I
kappaB I
were O
4 O
- O
8 O
times O
higher O
after O
CD80 B
compared O
to O
CD86 B
ligation O
. O

Defective O
binding O
and O
function O
of O
1 B
, I
25 I
- I
dihydroxyvitamin I
D3 I
receptors I
in O
peripheral O
mononuclear O
cells O
of O
patients O
with O
end O
- O
organ O
resistance O
to O
1 O
, O
25 O
- O
dihydroxyvitamin O
D O
. O

The O
presence O
of O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
was O
verified O
by O
: O
( O
a O
) O
adsorption O
of O
[ B
3H I
] I
TA I
- I
receptor I
- I
antibody I
complexes I
to O
Protein B
A I
; O
( O
b O
) O
a O
shift O
to O
higher O
apparent O
molecular O
weight O
in O
the O
elution O
position O
from O
Sephacryl O
S300 O
of O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
incubated O
with O
immune O
serum O
; O
and O
( O
c O
) O
the O
ability O
of O
immune O
serum O
to O
displace O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
on O
sucrose O
gradients O
. O

The O
presence O
of O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
was O
verified O
by O
: O
( O
a O
) O
adsorption O
of O
[ B
3H I
] I
TA I
- I
receptor I
- I
antibody I
complexes I
to O
Protein B
A I
; O
( O
b O
) O
a O
shift O
to O
higher O
apparent O
molecular O
weight O
in O
the O
elution O
position O
from O
Sephacryl O
S300 O
of O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
incubated O
with O
immune O
serum O
; O
and O
( O
c O
) O
the O
ability O
of O
immune O
serum O
to O
displace O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
on O
sucrose O
gradients O
. O

On O
DEAE O
- O
cellulose O
chromatography O
, O
[ B
3H I
] I
CVZ I
- I
receptor I
complexes I
show O
a O
shift O
from O
high O
( O
0 O
. O
25 O
M O
KP O
) O
to O
low O
salt O
( O
0 O
. O
09 O
M O
KP O
) O
eluting O
forms O
upon O
activation O
. O

Soluble O
receptor B
- I
- I
3H I
- I
steroid I
complex I
( O
cytosol O
or O
nuclear O
extract O
) O
is O
adsorbed O
quantitatively O
within O
the O
crevasses O
of O
porous O
glass O
beads O
. O

intracytoplasmic B
immunoglobulin I
A I
+ I
and I
G I
+ I
, O
BA B
- I
1 I
+ I
, O
polyclonal O
gammaglobulin O
production O
) O
; O
( O
2 O
) O
cytogenetic O
analysis O
of O
spontaneous O
metaphases O
revealed O
that O
in O
addition O
to O
the O
typical O
CLL O
abnormality O
, O
trisomy O
12 O
, O
in O
all O
of O
the O
cells O
, O
an O
additional O
translocation O
between O
chromosomes B
14 I
and I
17 I
was O
present O
in O
40 O
% O
with O
a O
presumptive O
breakpoint O
on O
chromosome B
14 I
( O
q12 O
- O
3 O
) O
never O
described O
before O
( O
commonly O
q32 O
) O
and O
( O
3 O
) O
the O
progression O
of O
the O
disease O
was O
associated O
with O
a O

Mutating O
the O
CD28RE B
but O
not O
the O
upstream B
nuclear I
factor I
kappabeta I
- I
binding I
site I
in O
the O
IL B
- I
2 I
promoter I
reduced O
B7 B
- I
1 I
- O
driven O
transcription O
> O
90 O
% O
. O

Inhibition O
of O
TNFalpha B
- O
induced O
NF O
- O
kappaB O
activation O
using O
the O
antioxidant O
N O
- O
acetylcysteine O
( O
NAC O
) O
resulted O
in O
increased O
apoptosis O
in O
both O
U937 O
and O
U9 O
- O
IIIB O
cells O
, O
while O
preactivation O
of O
NF B
- I
kappaB I
with O
the O
non B
- I
apoptotic I
inducer I
IL I
- I
1beta I
caused O
a O
relative O
decrease O
in O
apoptosis O
. O

Western O
blot O
analysis O
revealed O
that O
B O
cells O
express O
a O
variant O
form O
of O
the O
Ku86 B
protein I
with O
an O
apparent O
molecular O
weight O
of O
69 O
kDa O
, O
and O
not O
the O
86 B
kDa I
- I
full I
- I
length I
protein I
. O

Phosphorylation O
of O
the O
cAMP B
- I
response I
element I
binding I
protein I
CREB I
within O
1 O
h O
of O
CD2 B
but O
not O
CD3 B
cross O
- O
linking O
of O
human O
PBMC O
was O
recently O
demonstrated O
. O

As O
a O
result O
of O
this O
interaction O
, O
p12 B
( I
I I
) I
increases O
signal B
transducers I
and I
activators I
of I
transcription I
5 I
( O
STAT5 B
) O
DNA O
binding O
and O
transcriptional O
activity O
and O
this O
effect O
depends O
on O
the O
presence O
of O
both O
IL B
- I
2R I
beta I
and I
gamma I
( I
c I
) I
chains I
and O
Jak3 B
. O

Inhibition O
of O
pro B
- I
inflammatory I
transcription I
factors I
such O
as O
activator B
protein I
( I
AP I
) I
- I
1 I
, O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STATs B
) O
, O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
and O
nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
is O
thought O
to O
be O
a O
major O
action O
of O
glucocorticoids O
. O

GR B
acts O
as O
a O
direct O
inhibitor O
of O
NF O
- O
kappa O
B O
- O
induced O
HAT O
activity O
and O
also O
by O
recruiting O
HDAC2 B
to O
the O
NF B
- I
kappa I
B I
/ I
HAT I
complex I
. O

This O
induction O
was O
accompanied O
by O
augmented O
expression O
of O
the O
class B
B I
scavenger I
receptor I
CD36 I
( O
2 O
. O
8 O
+ O
/ O
- O
0 O
. O
3 O
- O
fold O
, O
P O
< O
0 O
. O
001 O
) O
but O
not O
by O
increased O
peroxisome B
proliferator I
- I
activated I
receptor I
- I
gamma I
expression O
. O

This O
is O
associated O
with O
enhanced O
phosphorylation O
of O
STAT1 B
, O
STAT3 B
, O
and O
Fyn B
, I
a I
Src I
homology I
tyrosine I
kinase I
, O
which O
interacts O
with O
both O
TCR O
and O
IFN O
- O
alpha O
signal O
components O
. O

Activation O
of O
the O
p21 B
( I
CIP1 I
/ I
WAF1 I
) I
promoter I
by O
bone B
morphogenetic I
protein I
- I
2 I
in O
mouse O
B O
lineage O
cells O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP B
- I
2 I
activated O
the O
mouse O
p21 B
( I
CIP1 I
/ I
WAF1 I
) I
promoter I
in O
HS O
- O
72 O
cells O
, O
and O
that O
a O
29 B
- I
base I
pair I
( I
b I
) I
region I
of O
the O
promoter O
( O
- O
1928 O
/ O
- O
1900 O
relative O
to O
the O
TATA B
box I
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP B
- I
2 I
as O
well O
as O
expression O
of O
Smad1 B
, O
Smad4 B
, O
and O
constitutively O
active O
mutants O
of O
BMP B
type I
I I
receptors I
. O

Macrophage O
stimulation O
with O
Murabutide O
, O
an O
HIV O
- O
suppressive O
muramyl O
peptide O
derivative O
, O
selectively O
activates O
extracellular B
signal I
- I
regulated I
kinases I
1 I
and I
2 I
, O
C B
/ I
EBPbeta I
and O
STAT1 B
: O
role O
of O
CD14 B
and O
Toll B
- I
like I
receptors I
2 I
and I
4 I
. O

Peritoneal O
fluid O
from O
patients O
with O
endometriosis O
activated O
U937 O
cells O
transiently O
transfected O
with O
a O
PPAR B
- I
alpha I
/ I
GAL4 I
luciferase I
reporter I
. O

The O
induction O
of O
IFN B
- I
regulatory I
factor I
- I
1 I
gene I
was O
comparable O
in O
transcription O
level O
in O
uninfected O
and O
infected O
cells O
, O
while O
the O
unidentified O
complex O
formation O
of O
IFN B
- I
regulatory I
factor I
- I
1 I
was O
observed O
in O
infected O
cells O
. O

Friend B
of I
GATA I
( I
FOG I
) I
proteins I
regulate O
GATA O
factor O
- O
activated O
gene O
transcription O
. O

We O
show O
here O
that O
T O
cell O
maturation O
depends O
on O
the O
presence O
of O
the O
beta B
- I
catenin I
- I
- I
binding I
domain I
in O
TCF B
- I
1 I
. O

Role O
of O
Mcl B
- I
1 I
, O
independent O
of O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
, O
Bad B
, O
or O
caspase O
activation O
. O

Here O
, O
we O
focused O
on O
the O
role O
of O
the O
PI3K B
- I
regulated I
serine I
/ I
threonine I
kinase I
Akt B
- I
1 I
in O
modulating O
macrophage O
survival O
. O

Inhibition O
of O
PI3K B
/ O
Akt O
- O
1 O
pathway O
either O
by O
LY294002 O
or O
DN B
Akt I
- I
1 I
had O
no O
effect O
on O
the O
constitutive O
or O
inducible O
activation O
of O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
in O
human O
macrophages O
. O

Fatty O
acids O
are O
ligands O
for O
peroxisome B
proliferator I
- I
activated I
receptor I
- I
gamma I
( O
PPARgamma B
) O
, O
and O
the O
upregulation O
of O
adipophilin B
mRNA I
by O
PPARgamma B
agonists O
like O
15d O
- O
PGJ O
( O
2 O
) O
and O
ciglitazone O
indicates O
that O
PPARgamma B
may O
mediate O
the O
induction O
of O
adipophilin O
expression O
in O
human O
blood O
monocytes O
. O

In O
agreement O
with O
the O
evidence O
of O
a O
coordinate O
transcription O
of O
the O
HLA B
- I
D I
genes I
in O
these O
cell O
lines O
, O
we O
have O
shown O
the O
constitutive O
expression O
of O
CIITA B
( I
class I
II I
transactivator I
) I
transcripts I
, O
CIITA B
being O
known O
as O
the O
master O
switch O
of O
MHC O
class O
II O
expression O
. O

METHODS O
: O
We O
prepared O
immature O
dendritic O
cells O
by O
incubating O
CD14 O
- O
positive O
cells O
in O
the O
presence O
of O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
and O
interleukin B
( I
IL I
) I
- I
4 I
. O

The O
nonobese O
patient O
with O
diabetes O
( O
NOD O
) O
mouse O
is O
a O
spontaneous O
model O
of O
type O
1 O
diabetes O
with O
a O
strong O
genetic O
component O
that O
maps O
to O
the O
major B
histocompatibility I
complex I
( I
MHC I
) I
region I
of O
the O
genome B
. O

We O
characterized O
the O
effects O
of O
type B
I I
IFN I
on O
the O
production O
of O
IL B
- I
12 I
, O
the O
central B
immunoregulatory I
cytokine I
of O
the O
CD4 B
( I
+ I
) I
T I
cell I
arm I
of O
CMI O
. O

To O
test O
these O
properties O
in O
humans O
, O
we O
investigated O
the O
effect O
of O
troglitazone O
on O
the O
proinflammatory B
transcription I
factor I
nuclear I
factor I
- I
kappaB I
and O
its O
inhibitory B
protein I
IkappaB I
in O
mononuclear O
cells O
( O
MNC O
) O
and O
plasma B
soluble I
intracellular I
adhesion I
molecule I
- I
1 I
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
plasminogen B
activator I
inhibitor I
- I
1 I
, O
and O
C B
- I
reactive I
protein I
. O

To O
test O
these O
properties O
in O
humans O
, O
we O
investigated O
the O
effect O
of O
troglitazone O
on O
the O
proinflammatory B
transcription I
factor I
nuclear I
factor I
- I
kappaB I
and O
its O
inhibitory B
protein I
IkappaB I
in O
mononuclear O
cells O
( O
MNC O
) O
and O
plasma B
soluble I
intracellular I
adhesion I
molecule I
- I
1 I
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
plasminogen B
activator I
inhibitor I
- I
1 I
, O
and O
C B
- I
reactive I
protein I
. O

Peroxizome B
proliferator I
- I
activated I
receptor I
- I
gamma I
( O
PPARgamma B
) O
is O
a O
member O
of O
the O
nuclear B
receptor I
family I
of O
transcription B
factors I
that O
regulate O
adipocyte O
differentiation O
. O

The O
tissue O
- O
and O
stage O
- O
specific O
assembly O
of O
Ig B
and I
TCR I
genes I
is O
mediated O
by O
a O
common O
V B
( I
D I
) I
J I
recombinase I
complex I
in O
precursor O
lymphocytes O
. O

We O
show O
that O
T B
- I
bet I
, O
without O
apparent O
assistance O
from O
interleukin B
12 I
( I
IL I
- I
12 I
) I
/ O
STAT4 B
, O
specifies O
TH1 O
effector O
fate O
by O
targeting O
chromatin O
remodeling O
to O
individual O
interferon B
- I
gamma I
( I
IFN I
- I
gamma I
) I
alleles I
and O
by O
inducing O
IL B
- I
12 I
receptor I
beta2 I
expression O
. O

Our O
studies O
indicate O
that O
Ii B
- O
induced O
B O
cell O
maturation O
involves O
activation O
of O
transcription O
mediated O
by O
the O
NF B
- I
kappaB I
p65 I
/ I
RelA I
homodimer I
and O
requires O
the O
B B
cell I
- I
enriched I
coactivator I
TBP B
- I
associated I
factor I
( I
II I
) I
105 I
. O

Inhibition O
of O
the O
transcription B
factors I
AP B
- I
1 I
and O
NF B
- I
kappaB I
in O
CD4 O
T O
cells O
by O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
ligands I
. O

The O
cytoplasmic B
domain I
of O
2B4 B
associates O
with O
src B
homology I
2 I
domain I
- I
containing I
protein I
or O
signaling B
lymphocyte I
activation I
molecule I
- I
associated I
protein I
, O
whose O
mutation O
is O
the O
underlying O
genetic O
defect O
in O
the O
X O
- O
linked O
lymphoproliferative O
syndrome O
. O

The O
cytoplasmic B
domain I
of O
2B4 B
associates O
with O
src B
homology I
2 I
domain I
- I
containing I
protein I
or O
signaling B
lymphocyte I
activation I
molecule I
- I
associated I
protein I
, O
whose O
mutation O
is O
the O
underlying O
genetic O
defect O
in O
the O
X O
- O
linked O
lymphoproliferative O
syndrome O
. O

Here O
we O
report O
that O
Cot B
kinase I
, O
a O
mitogen B
- I
activated I
protein I
kinase I
kinase I
kinase I
involved O
in O
T O
cell O
activation O
, O
up O
- O
regulates O
COX B
- I
2 I
gene I
expression O
in O
Jurkat O
T O
cells O
. O

Positive O
and O
negative O
roles O
of O
the O
trans B
- I
acting I
T I
cell I
factor I
- I
1 I
for O
the O
acquisition O
of O
distinct O
Ly B
- I
49 I
MHC I
class I
I I
receptors I
by O
NK O
cells O
. O

The O
acquisition O
of O
one O
Ly B
- I
49 I
receptor I
, O
Ly B
- I
49A I
is O
strictly O
dependent O
on O
the O
transcriptional B
trans I
- I
acting I
factor I
T B
cell I
- I
specific I
factor I
- I
1 I
( O
TCF B
- I
1 I
) O
. O

We O
found O
that O
ligation O
of O
CD11b B
or O
CD11c B
but O
not O
CD11a B
alpha I
chains I
of O
beta B
( I
2 I
) I
integrins I
by O
antibodies B
or O
soluble B
CD23 I
( I
sCD23 I
) I
fusion I
proteins I
rapidly O
induced O
transcription O
and O
secretion O
of O
interleukin B
8 I
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
1alpha I
, O
and O
MIP B
- I
1beta I
. O

We O
found O
that O
ligation O
of O
CD11b B
or O
CD11c B
but O
not O
CD11a B
alpha I
chains I
of O
beta B
( I
2 I
) I
integrins I
by O
antibodies B
or O
soluble B
CD23 I
( I
sCD23 I
) I
fusion I
proteins I
rapidly O
induced O
transcription O
and O
secretion O
of O
interleukin B
8 I
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
1alpha I
, O
and O
MIP B
- I
1beta I
. O

Acyl B
- I
coenzyme I
A I
: I
cholesterol I
acyltransferase I
( O
ACAT B
) O
is O
an O
intracellular B
enzyme I
involved O
in O
cellular O
cholesterol O
homeostasis O
and O
in O
atherosclerotic O
foam O
cell O
formation O
. O

We O
demonstrate O
here O
that O
human O
serum O
albumin O
modified O
with O
N O
( O
varepsilon O
) O
- O
( O
carboxymethyl O
) O
lysine O
( O
CML O
) O
, O
a O
major O
AGE O
adduct O
that O
progressively O
accumulates O
with O
aging O
, O
diabetes O
, O
and O
renal O
failure O
, O
induced O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
- O
driven O
reporter O
gene O
expression O
in O
human O
monocytic O
THP O
- O
1 O
cells O
. O

The O
NF B
- I
kappaB I
/ I
Rel I
transcription I
factors I
play O
an O
important O
role O
in O
the O
expression O
of O
genes O
involved O
in O
B O
cell O
development O
, O
differentiation O
and O
function O
. O

Interestingly O
, O
the O
pan B
- I
CD45 I
mAb I
GAP8 I
. I
3 I
, O
which O
is O
most O
effective O
in O
inhibition O
of O
OKT O
- O
3 O
- O
mediated O
proliferation O
in O
quiescent O
lymphocytes O
, O
was O
ineffective O
in O
lymphoblasts O
. O

The O
four O
calcium O
- O
regulated O
transcription B
factors I
of O
the O
NFAT B
family I
act O
synergistically O
with O
AP B
- I
1 I
( I
Fos I
/ I
Jun I
) I
proteins I
on O
composite O
DNA O
elements O
which O
contain O
adjacent O
NFAT B
and I
AP I
- I
1 I
binding I
sites I
, O
where O
they O
form O
highly O
stable O
ternary O
complexes O
to O
regulate O
the O
expression O
of O
diverse O
inducible O
genes O
. O

At O
variance O
with O
endotoxic O
lipopolysaccharide O
, O
plasmin B
elicited O
the O
rapid O
degradation O
of O
another O
cytoplasmic B
NF I
- I
kappaB I
inhibitor I
, I
p105 I
. O

While O
it O
has O
been O
shown O
that O
progenitor O
cells O
of O
P O
. O
vera O
patients O
are O
hypersensitive O
to O
several O
growth O
factors O
including O
erythropoietin B
, O
insulin B
- I
like I
growth I
factor I
- I
1 I
, O
thrombopoietin B
, O
interleukin B
- I
3 I
, O
and O
granulocyte B
/ I
monocyte I
colony I
- I
stimulating I
factor I
, O
the O
molecular O
pathogenesis O
of O
this O
disease O
remains O
unknown O
. O

While O
it O
has O
been O
shown O
that O
progenitor O
cells O
of O
P O
. O
vera O
patients O
are O
hypersensitive O
to O
several O
growth O
factors O
including O
erythropoietin B
, O
insulin B
- I
like I
growth I
factor I
- I
1 I
, O
thrombopoietin B
, O
interleukin B
- I
3 I
, O
and O
granulocyte B
/ I
monocyte I
colony I
- I
stimulating I
factor I
, O
the O
molecular O
pathogenesis O
of O
this O
disease O
remains O
unknown O
. O

Identification O
of O
phosphorylation B
sites I
for O
Bruton B
' I
s I
tyrosine I
kinase I
within O
the O
transcriptional B
regulator I
BAP I
/ I
TFII I
- I
I I
. O

Mutation O
of O
the O
nonconsensus B
- I
150 I
AP I
- I
1 I
site I
to O
a O
consensus B
AP I
- I
1 I
site I
, O
or O
insertion O
of O
a O
CD28RE B
/ I
AP I
- I
1 I
consensus I
site I
upstream O
of O
the O
native O
- B
150 I
CD28RE I
/ I
AP I
- I
1 I
site I
restored O
transactivation O
of O
the O
altered O
promoter B
. O

Mutation O
of O
the O
nonconsensus B
- I
150 I
AP I
- I
1 I
site I
to O
a O
consensus B
AP I
- I
1 I
site I
, O
or O
insertion O
of O
a O
CD28RE B
/ I
AP I
- I
1 I
consensus I
site I
upstream O
of O
the O
native O
- B
150 I
CD28RE I
/ I
AP I
- I
1 I
site I
restored O
transactivation O
of O
the O
altered O
promoter B
. O

Those O
cells O
were O
positive O
for O
stem B
cell I
markers I
, O
c B
- I
kit I
and O
CD34 B
, O
and O
a O
myeloid B
cell I
marker I
, I
F4 I
/ I
80 I
. O

Some O
cell O
fractions O
were O
also O
positive O
for O
Mac B
- I
1 I
, I
a I
macrophage I
marker I
or O
Gr B
- I
1 I
, I
a I
granulocytic I
maker I
, O
but O
negative O
for O
an O
erythroid B
marker I
TER119 I
. O

Some O
cell O
fractions O
were O
also O
positive O
for O
Mac B
- I
1 I
, I
a I
macrophage I
marker I
or O
Gr B
- I
1 I
, I
a I
granulocytic I
maker I
, O
but O
negative O
for O
an O
erythroid B
marker I
TER119 I
. O

BMI B
- I
1 I
and O
EZH2 B
Polycomb B
- I
group I
( I
PcG I
) I
proteins I
belong O
to O
two O
distinct O
protein O
complexes O
involved O
in O
the O
regulation O
of O
hematopoiesis O
. O

Core B
- I
binding I
factor I
beta I
( O
CBFbeta B
) O
, O
but O
not O
CBFbeta B
- I
smooth I
muscle I
myosin I
heavy I
chain I
, O
rescues O
definitive O
hematopoiesis O
in O
CBFbeta B
- O
deficient O
embryonic O
stem O
cells O
. O

Genes B
encoding I
CBFbeta I
( O
CBFB B
) O
, O
and O
one O
of O
the O
DNA B
- I
binding I
CBFalpha I
subunits I
, I
Runx1 I
( O
also O
known O
as O
CBFalpha2 B
, O
AML1 B
, O
and O
PEBP2alphaB B
) O
, O
are O
required O
for O
normal O
hematopoiesis O
and O
are O
also O
frequent O
targets O
of O
chromosomal O
translocations O
in O
acute O
leukemias O
in O
humans O
. O

Latent B
BHRF1 I
transcripts I
encoding O
bcl B
- I
2 I
homologue I
and O
BCRF1 B
transcripts I
encoding O
viral B
interleukin I
( I
vIL I
) I
- I
10 I
were O
detected O
in O
one O
and O
two O
of O
eight O
patients O
, O
respectively O
. O

Regulation O
of O
the O
human B
MAT2B I
gene I
encoding O
the O
regulatory B
beta I
subunit I
of O
methionine B
adenosyltransferase I
, O
MAT B
II I
. O

The O
MAT B
II I
isozyme I
consists O
of O
a O
catalytic B
alpha2 I
and I
a I
regulatory I
beta I
subunit I
. O

Furthermore O
, O
thymocytes O
and O
splenic O
T O
cells O
from O
lck O
- O
Mad1 O
transgenic O
mice O
display O
a O
profound O
proliferative O
defect O
in O
response O
to O
activation O
with O
either O
PMA O
/ O
Ionomycin O
or O
immobilized B
anti I
- I
CD3 I
/ I
CD28 I
antibody I
. O

Hypoxia B
inducible I
factor I
- I
1 I
( O
HIF B
- I
1 I
) O
is O
a O
constitutively O
expressed O
basic O
helix B
- I
loop I
- I
helix I
transcription I
factor I
, O
formed O
by O
the O
assembly O
of O
HIF B
- I
1alpha I
and O
HIF B
- I
1beta I
( O
Arnt B
) O
, O
that O
is O
stablized O
in O
response O
to O
hypoxia O
, O
and O
rapidly O
degraded O
under O
normoxic O
conditions O
. O

To O
determine O
the O
presence O
and O
potential O
role O
of O
BCL O
- O
6 O
mutations O
in O
cHD O
, O
the O
5 B
' I
- I
noncoding I
BCL I
- I
6 I
proportion O
of O
single O
Hodgkin O
and O
Reed O
- O
Sternberg O
( O
HRS O
) O
cells O
from O
6 O
cases O
of O
cHD O
and O
6 O
cases O
of O
HD O
- O
derived O
cell O
lines O
was O
analyzed O
. O

Naive O
CD8 O
( O
+ O
) O
Desire O
( O
Des O
) O
( O
+ O
) O
T O
cells O
isolated O
from O
the O
Des O
TCR O
- O
transgenic O
mice O
that O
are O
specific O
for O
the O
H B
- I
2K I
( I
b I
) I
class I
I I
Ag I
were O
transferred O
into O
Alb O
- O
K O
( O
b O
) O
- O
transgenic O
mice O
that O
express O
the O
H B
- I
2K I
( I
b I
) I
Ag I
on O
hepatocytes O
only O
. O

Stromal B
cell I
- I
derived I
factor I
1 I
alpha I
- O
induced O
chemotaxis O
in O
T O
cells O
is O
mediated O
by O
nitric O
oxide O
signaling O
pathways O
. O

Stromal B
cell I
- I
derived I
factor I
1 I
alpha I
( O
SDF1 B
alpha I
) O
and O
its O
cognate O
chemokine B
receptor I
CXCR4 I
act O
as O
potent O
chemoattractants O
and O
regulate O
trafficking O
and O
homing O
of O
hematopoietic O
progenitor O
cells O
and O
lymphocytes O
. O

Plasma B
tumor I
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
soluble B
intercellular I
adhesion I
molecule I
- I
1 I
( O
sICAM B
- I
1 I
) O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
, O
C B
- I
reactive I
protein I
( I
CRP I
) I
, O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
antiinflammatory B
cytokine I
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B
transcription I
factor I
NFkappaB I
. O

IL B
- I
6 I
upregulates O
suppressor B
of I
cytokine I
signaling I
1 I
( O
SOCS1 B
) O
expression O
in O
activated O
CD4 O
+ O
T O
cells O
, O
thereby O
interfering O
with O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
phosphorylation O
induced O
by O
interferon B
gamma I
( O
IFNgamma B
) O
. O

Interaction O
between O
CCAAT B
/ I
enhancer I
binding I
protein I
and O
cyclic B
AMP I
response I
element I
binding I
protein I
1 I
regulates O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
in O
cells O
of O
the O
monocyte O
/ O
macrophage O
lineage O
. O

Importantly O
, O
we O
demonstrate O
that O
one O
mechanism O
by O
which O
PI3 B
- I
K I
mediates O
the O
proliferation O
of O
infected O
B O
lymphocytes O
is O
through O
the O
induction O
of O
a O
granulocyte B
- I
monocyte I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
- O
dependent O
autocrine O
loop O
. O

Immunoglobulin B
( I
Ig I
) I
- I
kappa I
promoters I
from O
humans O
and O
mice O
share O
conserved B
sequences I
. O

Based O
on O
these O
data O
, O
and O
the O
conservation O
of O
the O
5 B
' I
- I
CAGCTG I
- I
3 I
' I
motif I
among O
human B
and I
murine I
kappa I
promoters I
, O
we O
propose O
that O
AP B
- I
4 I
is O
the O
major B
ligand I
for O
Ig B
- I
kappa I
promoter I
E I
- I
boxes I
. O

Pax B
- I
5a I
/ I
B I
cell I
- I
specific I
activator I
protein I
and O
an O
alternatively B
spliced I
isoform I
, I
Pax I
- I
5d I
, O
may O
have O
opposing O
functions O
in O
transcriptional O
regulation O
due O
to O
the O
lack O
of O
a O
transactivation B
domain I
in O
Pax B
- I
5d I
. O

NF B
- I
kappa I
B I
/ I
Rel I
participation O
in O
the O
lymphokine O
- O
dependent O
proliferation O
of O
T O
lymphoid O
cells O
. O

Gene O
regulation O
occurs O
via O
signal O
transduction O
pathways O
common O
to O
other O
innate O
immune O
responses O
, O
utilizing O
transcription B
factors I
such O
as O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
and O
NF B
interleukin I
- I
6 I
. O

Multiple O
signals O
required O
for O
cyclic B
AMP I
- I
responsive I
element I
binding I
protein I
( O
CREB B
) O
binding O
protein O
interaction O
induced O
by O
CD3 O
/ O
CD28 O
costimulation O
. O

Extracellular B
signal I
- I
regulated I
kinase I
, I
CaMKIV I
, O
and O
p38 B
MAPK I
were O
also O
the O
kinases O
involved O
in O
CREB B
Ser O
( O
133 O
) O
phosphorylation O
induced O
by O
CD3 B
/ I
CD28 I
. O

We O
had O
previously O
shown O
that O
activation O
of O
the O
arylhydrocarbon B
receptor I
( O
AHR B
) O
, O
a O
member O
of O
the O
bHLH B
- I
PAS I
family I
of I
transcription I
factors I
, O
leads O
to O
increased O
mRNA O
expression O
of O
IL B
- I
2 I
in O
murine O
fetal O
thymocytes O
. O

Binding O
motifs O
for O
the O
liganded B
AHR I
can O
be O
identified O
in O
the O
distal B
region I
- I
1300 I
to I
- I
800 I
of O
the O
mouse B
IL I
- I
2 I
promoter I
. O

Down O
- O
regulation O
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
and O
Oct2 B
in O
classical O
Hodgkin O
disease O
but O
not O
in O
lymphocyte O
predominant O
Hodgkin O
disease O
correlates O
with O
immunoglobulin O
transcription O
. O

As O
immunoglobulin O
transcription O
is O
mainly O
regulated O
by O
the O
B B
- I
cell I
transcription I
factors I
Oct2 B
and O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
, O
we O
analyzed O
35 O
cases O
of O
LPHD O
, O
32 O
cases O
of O
cHD O
, O
and O
2 O
Hodgkin O
disease O
cell O
lines O
for O
the O
expression O
of O
these O
transcription B
factors I
and O
also O
in O
parallel O
for O
immunoglobulin O
expression O
. O

Our O
results O
demonstrate O
an O
absence O
of O
Oct2 B
and O
/ O
or O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
in O
cHD O
and O
a O
striking O
overexpression O
of O
Oct2 B
in O
LPHD O
. O

Furthermore O
, O
the O
reintroduction O
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
and O
Oct2 B
into O
cultured O
HRS O
cells O
restored O
the O
activity O
of O
cotransduced O
immunoglobulin B
promoter I
constructs I
. O

Our O
findings O
dismiss O
the O
concept O
that O
the O
different O
immunoglobulin O
expression O
in O
cHD O
and O
LPHD O
is O
due O
to O
disrupting O
mutations O
of O
immunoglobulin B
V I
genes I
in O
cHD O
but O
is O
most O
likely O
due O
to O
a O
down O
- O
regulation O
of O
Oct2 B
and O
/ O
or O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
. O

The O
impairment O
of O
immunoglobulin O
transcription O
with O
a O
down O
- O
regulated O
synthesis O
of O
Oct2 B
and O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
is O
the O
first O
established O
general O
recurrent O
defect O
found O
in O
HRS O
cells O
. O

RESULTS O
: O
Induction O
of O
NF B
- I
kappaB I
DNA O
binding O
by O
the O
p65 B
( I
RelA I
) I
/ I
p50 I
heterodimer I
was O
observed O
in O
response O
to O
incubation O
of O
Mono O
Mac O
6 O
cells O
with O
SF O
( O
20 O
% O
in O
culture O
medium O
) O
from O
5 O
of O
8 O
subjects O
with O
RA O
, O
4 O
of O
5 O
with O
OA O
, O
and O
none O
of O
3 O
with O
undifferentiated O
seronegative O
oligoarthritis O
. O

Incubation O
of O
SF O
with O
neutralizing B
antibodies I
against O
tumor B
necrosis I
factor I
- I
alpha I
( I
TNF I
- I
alpha I
) I
, O
but O
not O
antibodies B
against O
interleukin B
6 I
( I
IL I
- I
6 I
) I
, O
significantly O
reduced O
the O
induction O
of O
p65 O
/ O
p50 O
binding O
activity O
in O
SF O
from O
subjects O
with O
RA O
and O
OA O
. O

Normal O
mouse O
B O
cells O
and O
a O
variety O
of O
B O
lymphoma O
cells O
reflective O
of O
stages O
of O
B O
cell O
differentiation O
( O
e O
. O
g O
. O
, O
70Z O
/ O
3 O
, O
CH31 O
, O
WEHI O
- O
231 O
, O
CH12 O
, O
and O
J558 O
) O
express O
PPAR B
- I
gamma I
mRNA I
and O
, O
by O
Western O
blot O
analysis O
, O
the O
67 B
- I
kDa I
PPAR I
- I
gamma I
protein I
. O

Suppression O
of O
HIV O
type O
1 O
replication O
by O
a O
dominant B
- I
negative I
Ets I
- I
1 I
mutant I
. O

The O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
play O
a O
critical O
role O
in O
the O
activity O
of O
the O
HIV B
- I
1 I
LTR I
distal I
enhancer I
region I
, O
as O
indicated O
by O
the O
potent O
dominant O
negative O
effect O
of O
a O
mutant B
Ets I
- I
1 I
lacking I
trans I
- I
activation I
domains I
on O
the O
transcriptional O
activity O
of O
the O
LTR B
. O

Eosinophil O
nuclear O
extracts O
contain O
multiple O
factors O
that O
can O
specifically O
recognize O
the O
IL B
- I
4 I
promoter I
P1 I
NFAT I
site I
in O
DNA O
- O
binding O
assays O
, O
including O
NFATp B
. O

Analysis O
of O
equilibrium O
binding O
of O
( B
125 I
) I
I I
- I
labeled I
BLyS I
to O
purified O
human O
tonsillar O
B O
cells O
demonstrated O
saturable O
binding O
. O

We O
demonstrate O
that O
Nef B
- I
ER I
inducibly O
associates O
with O
the O
62 B
- I
kDa I
Ser I
/ I
Thr I
kinase I
and O
is O
localized O
to O
specific O
membrane O
microdomains O
( O
lipid O
rafts O
) O
only O
after O
activation O
. O

HIV O
- O
1 O
- O
infected O
cells O
dose O
- O
dependently O
induced O
apoptotic O
commitment O
in O
normal O
PBMC O
, O
as O
revealed O
by O
DNA O
fragmentation O
analysis O
, O
but O
this O
was O
not O
accompanied O
by O
an O
increase O
of O
caspase O
- O
3 O
activity O
, O
even O
if O
a O
slight O
up O
- O
regulation O
of O
IL B
- I
1beta I
- I
converting I
enzyme I
mRNA I
was O
detected O
. O

Signaling O
via O
both O
the O
TCR B
and O
CD28 B
is O
required O
for O
optimal O
activation O
of O
the O
multisubunit B
IkappaB I
kinase I
( I
IKK I
) I
complex I
in O
primary O
human O
T O
lymphocytes O
; O
this O
activation O
could O
be O
inhibited O
by O
a O
Ca O
( O
2 O
+ O
) O
- O
independent O
PKC O
isoform O
inhibitor O
, O
rottlerin O
. O

In O
the O
five O
- O
protein O
system O
, O
Hip B
prevents O
inhibition O
of O
assembly O
by O
the O
hsp70 B
co I
- I
chaperone I
BAG I
- I
1 I
, O
and O
cotransfection O
of O
Hip B
with O
BAG B
- I
1 I
opposes O
BAG B
- I
1 I
reduction O
of O
steroid O
binding O
activity O
in O
COS O
cells O
. O

In O
addition O
, O
caspase B
- I
3 I
, O
an O
executioner O
of O
apoptosis O
, O
was O
activated O
and O
its O
substrate O
, O
poly B
( I
ADP I
- I
ribose I
) I
polymerase I
( O
PARP B
) O
, O
was O
cleaved O
during O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6 O
' O
- O
PeCB O
- O
induced O
apoptosis O
. O

IL B
- I
13 I
receptor I
alpha I
chain I
1 I
( O
IL B
- I
13R I
alpha I
1 I
) O
is O
necessary O
for O
binding O
to O
IL B
- I
13 I
, O
and O
the O
heterodimer O
composed O
of O
IL B
- I
13R I
alpha I
1 I
and O
IL B
- I
4R I
alpha I
chain I
transduces O
IL B
- I
13 I
and O
IL B
- I
4 I
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular B
domain I
of O
IL B
- I
13R I
alpha I
1 I
is O
not O
fully O
understood O
. O

Janus B
tyrosine I
kinase I
( I
Jak I
) I
3 I
and O
transcription B
factors I
Stat5a B
and O
Stat5b B
are O
essential O
for O
the O
proliferation O
of O
normal O
T O
cells O
and O
are O
constitutively O
hyperactivated O
in O
both O
HTLV O
- O
1 O
- O
transformed O
human O
T O
cell O
lines O
and O
lymphocytes O
isolated O
from O
HTLV O
- O
1 O
- O
infected O
patients O
; O
therefore O
, O
a O
critical O
role O
for O
the O
Jak3 O
- O
Stat5 O
pathway O
in O
the O
progression O
of O
this O
disease O
has O
been O
postulated O
. O

Bandshift O
studies O
indicate O
that O
this O
region O
contains O
three O
factor O
binding O
sites O
, O
termed O
sites B
B I
, I
C I
, I
and I
D I
, O
in O
addition O
to O
a O
previously O
characterized O
CREB B
site I
. O

To O
investigate O
the O
mechanism O
of O
such O
inhibition O
, O
the O
role O
of O
two O
mitogen O
- O
activated O
protein O
kinase O
pathways O
, O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
and O
extracellular B
signal I
- I
regulated I
kinase I
( O
ERK B
) O
, O
in O
modulating O
RXRE O
- O
dependent O
transcription O
, O
was O
explored O
. O

Proteasome O
inhibitors O
impaired O
internalization O
of O
IL B
- I
2 I
. I
IL I
- I
2R I
and O
prevented O
the O
lysosomal O
degradation O
of O
this O
cytokine B
. O

Based O
on O
time O
- O
course O
studies O
, O
proteasome B
activity O
is O
primarily O
required O
after O
initial O
endocytosis O
of O
the O
IL B
- I
2 I
. I
IL I
- I
2R I
. O

Proteasome O
function O
was O
also O
necessary O
for O
the O
lysosomal O
degradation O
of O
IL B
- I
2 I
internalized O
by O
IL B
- I
2R I
that O
were O
comprised O
of O
cytoplasmic B
tailless I
beta B
- I
or I
gamma I
c I
- I
subunits I
, O
suggesting O
that O
the O
target O
protein O
for O
the O
proteasome B
is O
independent O
of O
either O
the O
cytoplasmic B
tail I
of O
the O
IL B
- I
2R I
beta B
- I
or I
gamma I
c I
- I
subunits I
and O
their O
associated O
signaling O
components O
. O

Proteasome O
function O
was O
also O
necessary O
for O
the O
lysosomal O
degradation O
of O
IL B
- I
2 I
internalized O
by O
IL B
- I
2R I
that O
were O
comprised O
of O
cytoplasmic B
tailless I
beta B
- I
or I
gamma I
c I
- I
subunits I
, O
suggesting O
that O
the O
target O
protein O
for O
the O
proteasome B
is O
independent O
of O
either O
the O
cytoplasmic B
tail I
of O
the O
IL B
- I
2R I
beta B
- I
or I
gamma I
c I
- I
subunits I
and O
their O
associated O
signaling O
components O
. O

The O
time O
course O
of O
heme B
oxygenase I
- I
1 I
and I
- I
2 I
, O
cytokine B
- I
induced I
neutrophil I
chemoattractant I
- I
1 I
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
was O
studied O
by O
Northern O
analysis O
. O

The O
time O
course O
of O
heme B
oxygenase I
- I
1 I
and I
- I
2 I
, O
cytokine B
- I
induced I
neutrophil I
chemoattractant I
- I
1 I
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
was O
studied O
by O
Northern O
analysis O
. O

RESULTS O
: O
Acetaminophen O
caused O
a O
moderate O
sinusoidal O
perfusion O
failure O
( O
- O
15 O
% O
) O
and O
infiltration O
of O
neutrophils O
along O
with O
activation O
of O
nuclear B
factor I
- I
kappaB I
and O
intercellular B
adhesion I
molecule I
- I
1 I
and O
cytokine B
- I
induced I
neutrophil I
chemoattractant I
- I
1 I
mRNAs O
. O

Tumor B
necrosis I
factor I
- I
alpha I
- O
induced O
proliferation O
requires O
synthesis O
of O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
. O

RESULTS O
: O
All O
cell O
lines O
tested O
expressed O
TNF B
- I
alpha I
receptors I
I I
and I
II I
and O
responded O
to O
TNF B
- I
alpha I
by O
upregulation O
of O
intercellular B
adhesion I
molecule I
- I
1 I
. O

In O
contrast O
to O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
TNF B
- I
alpha I
did O
not O
activate O
the O
MAP B
kinase I
and O
p70S6 O
kinase O
pathways O
. O

Functional O
and O
physical O
interaction O
of O
protein B
- I
tyrosine I
kinases I
Fyn I
and I
Csk I
in O
the O
T O
- O
cell O
signaling O
system O
. O

The O
Src B
- I
like I
protein I
- I
tyrosine I
kinase I
Fyn B
is O
associated O
with O
T B
- I
cell I
antigen I
receptor I
. O

The O
stimulation O
of O
SRE B
was O
particularly O
prominent O
not O
only O
with O
active O
Fyn B
but O
also O
with O
normal B
( I
wild I
- I
type I
) I
Fyn I
. O

The O
predominant O
inducible O
form O
of O
the O
NF B
- I
kappa I
B I
transcription I
factor I
is O
a O
heteromeric B
complex I
containing O
two O
Rel B
- I
related I
DNA I
- I
binding I
subunits I
, O
termed B
p65 I
and O
p50 B
. O

This O
method O
utilises O
an O
immunomagnetic O
separation O
technique O
for O
B O
cell O
purification O
and O
a O
polymerase O
chain O
reaction O
( O
PCR O
) O
based O
assay O
for O
the O
determination O
of O
methylation O
status O
at O
the O
androgen B
receptor I
( I
AR I
) I
gene I
locus I
to O
assess O
whether O
X O
inactivation O
is O
random O
or O
non O
- O
random O
at O
this O
locus O
. O

Identification O
of O
a O
novel O
cyclosporin B
- I
sensitive I
element I
in O
the O
human B
tumor I
necrosis I
factor I
alpha I
gene I
promoter I
. O

In O
addition O
, O
nitric O
oxide O
greatly O
reduced O
the O
pertussis O
toxin O
- O
mediated O
ADP O
- O
ribosylation O
of O
45 B
- I
and I
41 I
- I
kDa I
proteins I
in O
membranes O
of O
these O
cells O
. O

Another O
factor O
resembled O
the O
T B
- I
cell I
- I
specific I
factor I
NFAT I
. O

By O
using O
a O
reporter O
- O
based O
expression O
approach O
, O
a O
T B
- I
cell I
- I
specific I
enhancer I
was O
identified O
by O
its O
close O
association O
with O
a O
prominent O
T B
- I
cell I
- I
restricted I
hypersensitive I
sites I
in O
the O
last O
intron O
of O
the O
CD8 B
alpha I
gene I
. O

Comparison O
of O
the O
CD8 B
alpha I
enhancer I
with O
other O
recently O
identified O
T B
- I
cell I
- I
specific I
regulatory I
elements I
suggests O
that O
a O
common O
set O
of O
transcription B
factors I
regulates O
several O
T B
- I
cell I
genes I
. O

Transient O
transfection O
studies O
in O
MLA O
- O
144 O
T O
cells O
revealed O
that O
constructs O
containing O
mutations O
in O
the O
AP B
- I
1 I
site I
almost O
completely O
abolished O
CAT O
activity O
while O
mutation O
of O
the O
Elf B
- I
1 I
site I
or O
the O
NF B
- I
IL I
- I
3 I
site I
, O
a O
previously O
described O
nuclear B
protein I
binding I
site I
( O
bp B
. I
- I
155 I
to I
- I
148 I
) O
in O
the O
IL B
- I
3 I
promoter I
, O
reduced O
CAT O
activity O
to O
< O
25 O
% O
of O
the O
activity O
given O
by O
wild O
- O
type O
constructs O
. O

Within O
this O
segment O
, O
a O
9 O
- O
mer O
motif O
( O
5 O
' O
- O
ACAGGAAGT O
- O
3 O
' O
, O
residues B
- I
505 I
to I
- I
497 I
; O
designated O
NF O
- O
P O
motif O
) O
, O
which O
is O
highly O
homologous O
to O
the O
Ets B
proto I
- I
oncoprotein I
- I
binding I
site I
, O
was O
found O
to O
interact O
with O
two O
proteins O
, O
NF B
- I
P1 I
and O
NF B
- I
P2 I
. O

In O
view O
of O
the O
homology O
between O
the O
NF B
- I
P I
motif I
and O
other O
Ets B
proto I
- I
oncoprotein I
- I
binding I
sites I
, O
it O
is O
postulated O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
belong O
to O
the O
Ets B
protein I
family I
. O

Results O
obtained O
from O
the O
binding O
competition O
assay O
, O
nevertheless O
, O
suggest O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
are O
related O
to O
but O
distinct O
from O
Ets B
proteins I
, O
e O
. O
g O
. O
, O
Ets B
- I
1 I
, O
Ets B
- I
2 I
, O
and O
NF B
- I
AT I
/ I
Elf I
- I
1 I
, O
known O
to O
be O
expressed O
in O
T O
cells O
. O

To O
evaluate O
the O
role O
of O
NF B
- I
kappa I
B I
in O
human O
peripheral O
blood O
T O
- O
lymphocytes O
, O
we O
previously O
analyzed O
the O
activation O
of O
NF B
- I
kappa I
B I
- I
related I
complexes I
in O
response O
to O
CD2 O
+ O
CD28 O
costimulation O
. O

We O
demonstrated O
a O
long O
- O
term O
induction O
of O
p50 B
/ I
p65 I
heterodimer I
, O
a O
putative B
p65 I
/ I
c I
- I
Rel I
heterodimer I
, O
and O
a O
constitutive O
nuclear O
expression O
of O
KBF1 B
/ I
p50 I
homodimers I
. I

ATP O
- O
depletion O
experiments O
suggest O
the O
existence O
of O
a O
nonbinding O
form O
of O
the O
receptor O
; O
` O
` O
chase O
' O
' O
experiments O
suggest O
reaction O
of O
hormone O
directly O
with O
nuclear O
- O
bound O
receptor O
; O
experiments O
on O
depletion O
and O
replenishment O
of O
cytoplasmic B
receptor I
using O
cortisol O
and O
dexamethasone O
suggest O
the O
existence O
of O
at O
least O
two O
subpopulations O
of O
nuclear B
- I
bound I
hormone I
- I
receptor I
complex I
. O

Multiple O
closely O
- O
linked O
NFAT B
/ I
octamer I
and O
HMG B
I I
( I
Y I
) I
binding I
sites I
are O
part O
of O
the O
interleukin O
- O
4 O
promoter O
. O

Three O
of O
the O
Il B
- I
4 I
NFAT I
- I
1 I
sites I
are O
closely O
linked O
to O
weak O
binding O
sites O
of O
Octamer B
factors I
. O

Several O
purine O
boxes O
and O
an O
AT B
- I
rich I
protein I
- I
binding I
site I
of O
the O
Il O
- O
4 O
promoter O
are O
also O
recognized O
by O
the O
high B
mobility I
group I
protein I
HMG B
I I
( I
Y I
) O
. O

We O
have O
tested O
whether O
breakdown O
of O
phosphatidylcholine O
( O
PC O
) O
initiated O
by O
exogenous O
addition O
of O
a O
PC B
- I
specific I
phospholipase I
C I
( O
PC B
- I
PLC I
) O
from O
Bacillus O
cereus O
or O
by O
endogenous O
overexpression O
of O
PC B
- I
PLC I
induces O
functional O
activation O
of O
NF B
- I
kappa I
B I
and O
increases O
human B
immunodeficiency I
virus I
( I
HIV I
) I
enhancer I
activity O
. O

PC O
- O
PLC O
- O
activated O
hydrolysis O
of O
PC O
was O
found O
to O
induce O
bona O
fide O
p50 B
/ I
p65 I
NF I
- I
kappa I
B I
binding O
activity O
in O
three O
different O
cell O
lines O
of O
human O
or O
murine O
origin O
. O

PC O
- O
PLC O
- O
induced O
NF O
- O
kappa O
B O
activation O
could O
not O
be O
blocked O
by O
a O
specific O
inhibitor O
of O
phorbol B
ester I
- I
inducible I
protein I
kinases I
C I
. O

This O
unique O
DNA O
binding O
activity O
consisted O
of O
proteins O
of O
70 B
, I
90 I
, I
and I
100 I
kDa I
with O
a O
high O
degree O
of O
binding O
specificity O
for O
the O
NF B
- I
kappa I
B I
site I
within O
the O
PRDII B
domain I
of O
beta B
interferon I
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

DNA O
binding O
of O
the O
90 B
- I
to I
100 I
- I
kDa I
proteins I
was O
not O
inhibited O
by O
recombinant B
I I
kappa I
B I
alpha I
/ I
MAD I
- I
3 I
and O
was O
resistant O
to O
tryptic O
digestion O
, O
suggesting O
that O
these O
proteins O
may O
not O
be O
NF B
- I
kappa I
B I
related I
. O

